0000950103-23-014246.txt : 20240108 0000950103-23-014246.hdr.sgml : 20240108 20230929102524 ACCESSION NUMBER: 0000950103-23-014246 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20230929 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVO NORDISK A S CENTRAL INDEX KEY: 0000353278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 BUSINESS PHONE: 4544448888 MAIL ADDRESS: STREET 1: NOVO ALLE DK 2880 CITY: BAGSVAERD DENMARK STATE: G7 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: NOVO NORDISK A/S DATE OF NAME CHANGE: 19900807 FORMER COMPANY: FORMER CONFORMED NAME: NOVO INDUSTRI A S /DENMARK/ DATE OF NAME CHANGE: 19890811 CORRESP 1 filename1.htm

Leo Borchardt

+44 20 7418 1334

leo.borchardt@davispolk.com

Davis Polk & Wardwell London llp

5 Aldermanbury Square
London EC2V 7HR

davispolk.com

September 29, 2023

Re:	Novo Nordisk A/S Form 20-F for the Fiscal Year Ended December 31, 2022 Filed February 1, 2023 File Number: 333-82318

Anuja A. Majmudar

Karina Dorin
U.S. Securities and Exchange Commission
Division of Corporation Finance

Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549

Dear Ms. Majmudar and Ms. Dorin:

I am writing on behalf of Novo Nordisk A/S (the “Company”) in connection with the Staff’s review of the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2022. I confirm that the Company has received and is considering its response to your letter dated September 27, 2023.

In order to ensure the completeness and accuracy of the Company’s response, it will be conducting a detailed review of the items concerned in respect of the above filing.

The Company anticipates being able to complete this review and provide a response to the SEC by no later than Friday, October 20, 2023.

Very truly yours,

/s/ Leo Borchardt

Leo Borchardt

cc:

Karsten Munk Knudsen
Novo Nordisk A/S

Via Edgar Submission

GRAPHIC 2 image_001.gif GRAPHIC begin 644 image_001.gif M1TE&.#EA:0 3 '< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y M! $ + !I !$ @ +8C(^@R^V_#IRH3FJ4A+6'"W)9R'@) MJ8W;8UHHN:)M#&YT2;OO+H_1C?D @"G?+W?B-9)+8U'X=-B<..IPU;HZ)5B/ ME'HR58O5#_,HM(1C7%7B?'MGR5ITE.6&:LWLS%3/A.37ET>7='84Q.?S=Z9E@=7R=C9F+FG\Q2J9PA*:;4V"FKJZ7KAR;JY]]5F M=#@(1:2;&+2+ZS@#VQ3K^[E*:$O8C F+?,S\+)QM*B)FG'J:FWJ)!KB,NLV- 16AHUQRGY/4S."7.^_E0 #L! end